Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts…
Community, Culture, Applications & Art
Explore the main themes, entities and connections around Erlotinib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
egfr cancer lung receptor epidermal growth factor effects patients may use side drug tyrosine kinase rash liver resistance treatment pancreatic
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Erlotinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Erlotinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Erlotinib | ATC code | L01EB02 (WHO) | 1.00 | infobox |
| Erlotinib | Bioavailability | 59% | 1.00 | infobox |
| Erlotinib | CAS Number | 183321-74-6 Y | 1.00 | infobox |
| Erlotinib | ChEBI | CHEBI:114785 Y | 1.00 | infobox |
| Erlotinib | ChEMBL | ChEMBL553 Y | 1.00 | infobox |
| Erlotinib | ChemSpider | 154044 Y | 1.00 | infobox |
| Erlotinib | CompTox Dashboard (EPA) | DTXSID8046454 | 1.00 | infobox |
| Erlotinib | DrugBank | DB00530 Y | 1.00 | infobox |
| Erlotinib | ECHA InfoCard | 100.216.020 | 1.00 | infobox |
| Erlotinib | Elimination half-life | 36.2 hrs (median) | 1.00 | infobox |
| Erlotinib | Excretion | >98% as metabolites, of which >90% via feces, 9% via urine | 1.00 | infobox |
| Erlotinib | Formula | C22H23N3O4 | 1.00 | infobox |
| Erlotinib | IUPHAR/BPS | 4920 | 1.00 | infobox |
| Erlotinib | KEGG | D07907 Y | 1.00 | infobox |
| Erlotinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Erlotinib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Erlotinib | Legal status | US: ℞-only | 1.00 | infobox |
| Erlotinib | License data | US DailyMed: Erlotinib | 1.00 | infobox |
| Erlotinib | MedlinePlus | a605008 | 1.00 | infobox |
| Erlotinib | Metabolism | Liver (mainly CYP3A4, less CYP1A2) | 1.00 | infobox |
| Erlotinib | Molar mass | 393.443 g·mol−1 | 1.00 | infobox |
| Erlotinib | Other names | Erlotinib hydrochloride | 1.00 | infobox |
| Erlotinib | Pregnancy category | AU: C | 1.00 | infobox |
| Erlotinib | Protein binding | 95% | 1.00 | infobox |
| Erlotinib | PubChem CID | 176870 | 1.00 | infobox |
| Erlotinib | Routes of administration | By mouth | 1.00 | infobox |
| Erlotinib | Trade names | Tarceva | 1.00 | infobox |
| Erlotinib | UNII | J4T82NDH7E | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.